While UroGen Pharma Ltd has overperformed by 2.35%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, URGN rose by 5.53%, with highs and lows ranging from $20.70 to $10.60, whereas the simple moving average fell by -17.55% in the last 200 days.
On August 22, 2024, Guggenheim started tracking UroGen Pharma Ltd (NASDAQ: URGN) recommending Buy. A report published by Jefferies on February 08, 2023, Downgraded its rating to ‘Hold’ for URGN. Berenberg also rated URGN shares as ‘Buy’, setting a target price of $20 on the company’s shares in an initiating report dated April 27, 2022. H.C. Wainwright Reiterated the rating as Buy on April 16, 2020, but set its price target from $53 to $57. H.C. Wainwright resumed its ‘Buy’ rating for URGN, as published in its report on April 13, 2020. National Securities’s report from January 09, 2020 suggests a price prediction of $37 for URGN shares, giving the stock a ‘Neutral’ rating. JP Morgan also rated the stock as ‘Neutral’.
Analysis of UroGen Pharma Ltd (URGN)
Further, the quarter-over-quarter increase in sales is 3.35%, showing a positive trend in the upcoming months.
UroGen Pharma Ltd’s future performance can be determined with the help of several well-rounded types of analysis and research techniques, with equity being one of the most influential. Taking into account the quick ratio of the company, currently set at 7.93, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
The average volume for any stock is also a very valuable indicator of volatility, and URGN has an average volume of 589.40K. On a monthly basis, the volatility of the stock is set at 6.39%, whereas on a weekly basis, it is put at 6.30%, with a loss of -0.33% over the past seven days. Furthermore, long-term investors anticipate a median target price of $40.75, showing growth from the present price of $12.21, which can serve as yet another indication of whether URGN is worth investing in or should be passed over.
How Do You Analyze UroGen Pharma Ltd Shares?
In addition to analyzing the fundamentals, it is also important to look at how many company employees own stock. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 9.30%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 98.32% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
URGN shares are owned by institutional investors to the tune of 98.32% at present.
